PDCD1 and neoplasm: Studies have shown that the expression of PD-L1 and the presence of exhausted tumor-infiltrating lymphocytes (TILs) expressing multiple immune checkpoints, including PD-1, are indicative of an adaptive resistance mechanism to anti-PD-1/PD-L1 therapy [82–84].